Lucid Diagnostics (NASDAQ:LUCD) Given “Buy” Rating at Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report report published on Thursday morning,Benzinga reports. They currently have a $3.00 target price on the stock.

LUCD has been the topic of several other reports. Needham & Company LLC reissued a “buy” rating and issued a $2.50 price target on shares of Lucid Diagnostics in a report on Thursday. Canaccord Genuity Group raised shares of Lucid Diagnostics to a “strong-buy” rating in a report on Tuesday, August 13th. Finally, Ascendiant Capital Markets decreased their target price on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a research report on Tuesday, September 10th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $3.69.

Lucid Diagnostics Price Performance

NASDAQ:LUCD traded down $0.03 on Thursday, hitting $0.98. 386,203 shares of the company’s stock were exchanged, compared to its average volume of 195,014. The firm has a 50-day moving average price of $0.87 and a 200-day moving average price of $0.85. Lucid Diagnostics has a 52 week low of $0.63 and a 52 week high of $1.58. The company has a market cap of $52.99 million, a P/E ratio of -0.88 and a beta of 1.41.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $0.98 million for the quarter. On average, research analysts expect that Lucid Diagnostics will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lucid Diagnostics

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC grew its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 34,671 shares of the company’s stock after acquiring an additional 13,835 shares during the period. Virtu Financial LLC owned about 0.07% of Lucid Diagnostics worth $28,000 as of its most recent SEC filing. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.